AR099874A1 - CROMENO Y 1,1A,2,7B-TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS COMO MODULADORES DE g-SECRETASA - Google Patents

CROMENO Y 1,1A,2,7B-TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS COMO MODULADORES DE g-SECRETASA

Info

Publication number
AR099874A1
AR099874A1 ARP150100922A ARP150100922A AR099874A1 AR 099874 A1 AR099874 A1 AR 099874A1 AR P150100922 A ARP150100922 A AR P150100922A AR P150100922 A ARP150100922 A AR P150100922A AR 099874 A1 AR099874 A1 AR 099874A1
Authority
AR
Argentina
Prior art keywords
alkoxy
alkyl
group
hydroxy
cycloalkyl
Prior art date
Application number
ARP150100922A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52815058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR099874(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of AR099874A1 publication Critical patent/AR099874A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP150100922A 2014-04-01 2015-03-27 CROMENO Y 1,1A,2,7B-TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS COMO MODULADORES DE g-SECRETASA AR099874A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461973436P 2014-04-01 2014-04-01

Publications (1)

Publication Number Publication Date
AR099874A1 true AR099874A1 (es) 2016-08-24

Family

ID=52815058

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100922A AR099874A1 (es) 2014-04-01 2015-03-27 CROMENO Y 1,1A,2,7B-TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS COMO MODULADORES DE g-SECRETASA

Country Status (29)

Country Link
US (2) US20150274721A1 (enExample)
EP (1) EP3126361B1 (enExample)
JP (1) JP6643247B2 (enExample)
KR (1) KR101886945B1 (enExample)
CN (1) CN106211770B (enExample)
AP (1) AP2016009465A0 (enExample)
AR (1) AR099874A1 (enExample)
AU (1) AU2015242330B2 (enExample)
BR (1) BR112016022519A8 (enExample)
CA (1) CA2944308A1 (enExample)
CL (1) CL2016002422A1 (enExample)
CR (1) CR20160454A (enExample)
CU (1) CU20160140A7 (enExample)
DK (1) DK3126361T3 (enExample)
DO (1) DOP2016000266A (enExample)
EA (1) EA031419B1 (enExample)
EC (1) ECSP16078289A (enExample)
ES (1) ES2759277T3 (enExample)
IL (1) IL248154B (enExample)
MD (1) MD20160102A2 (enExample)
MX (1) MX369074B (enExample)
NI (1) NI201600149A (enExample)
PE (1) PE20161364A1 (enExample)
PH (1) PH12016501864A1 (enExample)
SG (1) SG11201607465UA (enExample)
TW (1) TWI568733B (enExample)
UY (1) UY36054A (enExample)
WO (1) WO2015150957A1 (enExample)
ZA (1) ZA201606252B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
MX368391B (es) * 2015-02-03 2019-09-30 Pfizer Ciclopropabenzofuranil-piridopirazindionas novedosas.
CN106580997B (zh) * 2016-12-09 2018-01-19 张田 一种治疗先兆流产的药物组合物
CA3047096A1 (en) 2016-12-16 2018-06-21 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
EP3849979A1 (en) * 2018-09-12 2021-07-21 Novartis AG Antiviral pyridopyrazinedione compounds
CN110907542A (zh) * 2018-09-17 2020-03-24 复旦大学 一种液质联用检测唾液中司来吉兰及其代谢物的方法
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
US12240855B2 (en) 2019-03-06 2025-03-04 Daiichi Sankyo Company, Limited Pyrrolopyrazole derivative
KR20250127350A (ko) 2019-09-26 2025-08-26 노파르티스 아게 항바이러스성 피라졸로피리디논 화합물
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
CN120129681A (zh) 2022-10-18 2025-06-10 辉瑞大药厂 含Patatin样磷脂酶结构域的蛋白3(PNPLA3)调节剂

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239797T1 (de) 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
US8173127B2 (en) 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
SI0994728T1 (sl) 1997-04-09 2009-02-28 Intellect Neurosciences Inc Rekombinantna protitelesa, specifična za beta-amiloidne konce, kodirana z DNA ter postopki za njihovo uporabo
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
EP3150633A1 (en) 2000-02-24 2017-04-05 Washington University St. Louis Humanized antibodies that sequester amyloid beta peptide
DE10045112A1 (de) 2000-09-11 2002-03-21 Merck Patent Gmbh Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems
AU2002239764B2 (en) 2000-11-03 2007-06-21 Proteotech, Inc. Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Aβ抗体
US20030195205A1 (en) 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
SI1480983T1 (sl) * 2002-02-28 2006-04-30 Sanofi Aventis Heteroarilno substituirani 2-piridinil in 2-pirimidinil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-onski derivati
DE10238724A1 (de) 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238723A1 (de) 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
WO2004032868A2 (en) 2002-10-09 2004-04-22 Rinat Neuroscience Corp. Methods of treating alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
EP1638935A1 (en) 2003-06-19 2006-03-29 Pfizer Products Inc. Nk1 antagonist
WO2005025616A1 (ja) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited 抗体の用途
GB0327319D0 (en) 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
JP2007519707A (ja) 2004-02-02 2007-07-19 ファイザー・プロダクツ・インク ヒスタミン−3受容体モジュレーター
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
AP2007003890A0 (en) 2004-07-30 2007-02-28 Rinat Neuroscience Corp Antibodies directed against amy-loid-beta peptide and methods using same
GB0423356D0 (en) 2004-10-21 2004-11-24 Merck Sharp & Dohme Therapeutic agents
EP1827493A4 (en) 2004-12-22 2009-09-30 Univ St Louis USE OF ANTI-ABETA ANTIBODIES FOR THE TREATMENT OF BRAIN TRAUMA
PE20061323A1 (es) 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
US8227475B2 (en) 2005-05-12 2012-07-24 Pfizer Inc. Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
CA2603830A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Co Llc PYRIDINE [2,3-B] PYRAZINONES
CA2608672A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
ATE488496T1 (de) 2005-06-22 2010-12-15 Pfizer Prod Inc Histamin-3-rezeptorantagonisten
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007052124A1 (en) 2005-11-04 2007-05-10 Pfizer Limited Tetrahydronaphthyridine derivative
WO2007063385A2 (en) 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2007069053A1 (en) 2005-12-14 2007-06-21 Pfizer Products Inc. Benzimidazole antagonists of the h-3 receptor
WO2007088462A1 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Spirochromane antagonists of the h-3 receptor
WO2007088450A2 (en) 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2007099423A1 (en) 2006-03-02 2007-09-07 Pfizer Products Inc. 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
CA2643055A1 (en) 2006-03-13 2007-09-20 Pfizer Products Inc. Tetralines antagonists of the h-3 receptor
PL2013208T3 (pl) 2006-04-21 2011-10-31 Pfizer Prod Inc Pirydyno[3,4-B]pirazynowy
WO2007138431A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Azabicyclic ether histamine-3 antagonists
BRPI0806473A2 (pt) 2007-01-22 2011-09-27 Pfizer Prod Inc sal de tosilato de um composto terapêutico e composições farmacêuticas do mesmo
JP2012506857A (ja) * 2008-10-23 2012-03-22 メルク・シャープ・エンド・ドーム・コーポレイション 縮合複素環式m1受容体ポジティブアロステリック調節因子
WO2012131539A1 (en) * 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
MX355164B (es) * 2012-05-16 2018-04-06 Janssen Pharmaceuticals Inc Derivados de 3,4-dihidro-2h-pirido[1,2-a]pirazin-1,6-diona sustituidos utiles para el tratamiento de la enfermedad de alzheimer (inter alia).
UA110688C2 (uk) * 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
ES2612215T3 (es) * 2013-01-17 2017-05-12 Janssen Pharmaceutica, N.V. Novedosos derivados de pirido-piperazinona sustituidos como moduladores de gamma secretasa
JP6425717B2 (ja) * 2013-10-04 2018-11-21 ファイザー・インク ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン

Also Published As

Publication number Publication date
MX2016012904A (es) 2016-12-07
PH12016501864A1 (en) 2016-12-19
WO2015150957A1 (en) 2015-10-08
BR112016022519A8 (pt) 2018-03-06
MX369074B (es) 2019-10-28
TW201540716A (zh) 2015-11-01
SG11201607465UA (en) 2016-10-28
EP3126361B1 (en) 2019-11-06
IL248154B (en) 2020-09-30
ECSP16078289A (es) 2017-02-24
EA031419B1 (ru) 2018-12-28
AU2015242330B2 (en) 2017-08-17
CL2016002422A1 (es) 2017-02-03
DK3126361T3 (da) 2020-01-02
TWI568733B (zh) 2017-02-01
DOP2016000266A (es) 2016-11-15
AU2015242330A1 (en) 2016-09-22
KR101886945B1 (ko) 2018-08-08
PE20161364A1 (es) 2016-12-25
ES2759277T3 (es) 2020-05-08
CR20160454A (es) 2016-12-06
ZA201606252B (en) 2018-05-30
CN106211770B (zh) 2018-02-06
JP6643247B2 (ja) 2020-02-12
HK1231481A1 (zh) 2017-12-22
CN106211770A (zh) 2016-12-07
US20150274721A1 (en) 2015-10-01
CU20160140A7 (es) 2017-02-02
BR112016022519A2 (pt) 2017-08-15
JP2017512803A (ja) 2017-05-25
CA2944308A1 (en) 2015-10-08
EA201600619A1 (ru) 2017-03-31
AP2016009465A0 (en) 2016-09-30
MD20160102A2 (ro) 2017-04-30
EP3126361A1 (en) 2017-02-08
UY36054A (es) 2015-10-30
US20170166566A1 (en) 2017-06-15
KR20160137635A (ko) 2016-11-30
NI201600149A (es) 2016-11-18
IL248154A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
AR099874A1 (es) CROMENO Y 1,1A,2,7B-TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS COMO MODULADORES DE g-SECRETASA
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
MX389349B (es) Derivados de ácido borónico y usos terapéuticos de los mismos.
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
MX2018003432A (es) Compuestos heterociclicos y usos de los mismos.
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
SV2018005778A (es) Derivados aromaticos de sulfonamida
EA201691579A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
AR092742A1 (es) Piridinonas antifibroticas
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
AR094174A1 (es) Lactamas fusionadas de arilo y heteroarilo
AR088760A1 (es) Derivados de pirrolopirimidina y purina
CL2015003569A1 (es) “compuestos derivados de (aril ó heteroaril)metil-2-(aril, heterociclil, cicloalquil ó alquil)-1,3-dioxan-metoxi-fenil-piperazin-1-il-fenil-heterociclil sustituido; composición farmacéutica que los comprende; su uso en el tratamiento de la fibrosis”. pct
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
NI201200191A (es) Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
MX387483B (es) Preparación farmacéutica.
AR094550A1 (es) Inhibidores de btk
PE20160605A1 (es) Formulaciones de inhibidores de la syk
EA201692003A1 (ru) Макроциклические производные пиримидина
AR104461A1 (es) Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil, pirrolo[2,3-b]piridinil acrilamidas y epóxidos de estas
AR098492A1 (es) Derivados de purina
AR097894A1 (es) Inhibidores terapéuticos de cdk8 o uso de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure